CARVEDILOL ( DrugBank: Carvedilol )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
57	特発性拡張型心筋症	1
86	肺動脈性肺高血圧症	6
113	筋ジストロフィー	4
210	単心室症	1

57. 特発性拡張型心筋症

臨床試験数 : 11 / 薬物数 : 23 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01798992 (ClinicalTrials.gov)	September 2000	22/2/2013	Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart	Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart	Idiopathic Dilated Cardiomyopathy	Drug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosin	University of Colorado, Denver	National Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZeneca	Completed	18 Years	N/A	All	56	Phase 4	United States

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02507011 (ClinicalTrials.gov)	January 31, 2016	22/7/2015	Beta-blockers in Pulmonary Arterial Hypertension	Beta-blockers in Pulmonary Arterial Hypertension - A Phase 2 Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy, and Safety of Carvedilol for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Carvedilol;Drug: Placebo	University of Minnesota	NULL	Terminated	18 Years	N/A	All	2	Phase 2	United States
2	NCT02120339 (ClinicalTrials.gov)	May 2014	17/4/2014	Carvedilol PAH A Pilot Study of Efficacy and Safety	Beta Blockers in Pulmonary Arterial Hypertension (PAH) A Pilot Study of Efficacy and Safety	Pulmonary Hypertension;Cardiac MRI <40	Drug: Carvedilol	University of Minnesota	NULL	Terminated	18 Years	99 Years	All	5	Phase 1	United States
3	NCT01586156 (ClinicalTrials.gov)	December 2012	23/4/2012	PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)	Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure	Pulmonary Hypertension	Drug: Carvedilol;Drug: placebo	The Cleveland Clinic	National Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	65 Years	All	30	N/A	United States
4	NCT01723371 (ClinicalTrials.gov)	September 2012	31/10/2012	Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children	Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children	Pulmonary Arterial Hypertension	Drug: Carvedilol	The Hospital for Sick Children	NULL	Withdrawn	8 Years	17 Years	Both	0	Phase 1/Phase 2	Canada
5	NCT00964678 (ClinicalTrials.gov)	June 2010	24/8/2009	Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension	Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Carvedilol	Virginia Commonwealth University	GlaxoSmithKline	Completed	18 Years	N/A	All	10	Phase 1/Phase 2	United States
6	NCT00240656 (ClinicalTrials.gov)	October 2005	17/10/2005	Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension	Official Title: Spironolactone Combined With Captopril and Carvedilol for the Treatment of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease—Focus on Pulmonary Artery Remodeling	Hypertension, Pulmonary	Drug: spironolactone captopril carvedilol	Hebei Medical University	NULL	Completed	N/A	80 Years	Both		Phase 1	China

先頭へ

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-007236-18-IT (EUCTR)	01/12/2008	11/12/2008	Effects of cardioprotective therapy, carvedilol vs ramipril, in patients affected by Duchenne and Becker muscular dystrophy. Clinical significance and prognostic value of Cardiac Magnetic Resonance study. - ND	Effects of cardioprotective therapy, carvedilol vs ramipril, in patients affected by Duchenne and Becker muscular dystrophy. Clinical significance and prognostic value of Cardiac Magnetic Resonance study. - ND	Duchenne and Becher muscular dystrophy MedDRA version: 9.1;Level: LLT;Classification code 10013801;Term: Duchenne muscular dystrophy	Trade Name: DILATREND INN or Proposed INN: Carvedilol Trade Name: TRIATEC INN or Proposed INN: Ramipril	POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI	NULL	Not Recruiting			Female: no Male: yes			Italy
2	NCT00819845 (ClinicalTrials.gov)	December 2008	8/1/2009	Ramipril Versus Carvedilol in Duchenne and Becker Patients	Effects of Cardioprotective Therapy, Carvedilol vs Ramipril, in Patients Affected by Duchenne and Becker Muscular Dystrophy. Clinical Significance and Prognostic Value of Cardiac Magnetic Resonance Study.	Duchenne Muscular Dystrophy;Becker Muscular Dystrophy	Drug: carvedilol;Drug: ramipril	Catholic University, Italy	NULL	Recruiting	2 Years	45 Years	Male	194	Phase 4	Italy
3	NCT00606775 (ClinicalTrials.gov)	December 2007	22/1/2008	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy	Carvedilol for the Prevention of Minor Cardiac Damage and Cardiac Function in Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy;Cardiomyopathies	Drug: Carvedilol	Suzuka Hospital	Nagoya University	Recruiting	8 Years	45 Years	Male	60	Phase 4	Japan
4	EUCTR2006-003075-12-IE (EUCTR)		13/07/2006	Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction.	Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction.	Duchenne muscular dystrophy is an X-linked inherited disorder which primarily affects skeletal muscle through a mutation in dystrophin which maps to the long arm of the X chromosome (Xp21). Patients with skeletal myopathy such as DMD eventually progress to develop dilated cardiomyopathy as dystrophin is expressed in all forms of muscle including cardiac and smooth muscle. Often the cause of death in patients with DMD is cardiac failure and arrhythmia.	Trade Name: Eucardic Product Name: Eucardic Product Code: No code INN or Proposed INN: CARVEDILOL	Department Of Paediatric Cardiology	NULL	NA			Female: yes Male: yes	30	Phase 4	Ireland

210. 単心室症

臨床試験数 : 51 / 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02946892 (ClinicalTrials.gov)	November 2016	23/9/2016	Effect of Carvedilol on Exercise Performance in Fontan Patients	Effect of Carvedilol on Exercise Performance in Fontan Patients	Single Ventricle;Fontan	Drug: Carvedilol;Drug: Placebo	University of Texas Southwestern Medical Center	American Heart Association	Completed	10 Years	35 Years	All	26	Phase 4	United States

先頭へ